Together with B. Braun Group, Christoph Miethke GmbH & Co. KG is proud of its innovations for hydrocephalus patients

19/06/2025

Together with B. Braun Group, Christoph Miethke GmbH & Co. KG is proud of its innovations for hydrocephalus patients. Company’s M.scio® is a telemetric intracranial pressure (ICP) monitoring device designed for long-term implantation. With a high sampling rate of 44Hz, M.scio® delivers detailed pressure curves and clinically relevant ICP morphologies, making it invaluable for both acute and long-term patient management. 

Primarily used alongside a shunt for patients with complex hydrocephalus, it plays a critical role in addressing shunt-related complications, cerebrospinal fluid (CSF) disturbances and ICP management.

Unlike traditional methods, M.scio® enables precise, non-invasive real-time ICP monitoring without the need for zeroing or complicated set-ups. M.scio® provides reliable readings with minimal drift (less than 2 mmHg) over a period of four years, ensuring that clinicians have consistent and accurate data at their disposal.

M.scio® is available in four designs, featuring dome or flat housings. Whilst flat variants are recommended for patients with space restriction such as paediatrics, the dome variants mirror conventional reservoirs. These reservoirs not only monitor ICP but also facilitate therapeutic interventions like CSF withdrawal, diagnostic sampling, and fluid administration. This flexibility enhances both its efficacy and usability.

Seventy percent of patients reported clinical improvement after receiving the implant, and follow-up studies revealed a 75% improvement in symptoms after two years.